1. Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?

3. Introduction

4. Clinical Case Presentation

5. ADA Practice Guidelines

6. ADA Practice Guidelines (cont)

7. EDITION I to III Meta-Analysis: Summary

8. Advantages of New Insulin Analogues

9. EDITION I to III Meta-Analysis: Severe or Confirmed Hypoglycemia ≤ 3
EDITION I to III Meta-Analysis: Severe or Confirmed Hypoglycemia ≤ 3.9 mmol/L (70 mg/dL)

10. SWITCH 2: Trial Population

11. SWITCH: Hypoglycemia Risk Inclusion Criteria

12. SWITCH 2: Overall Symptomatic Hypoglycemia - IDeg Significantly Reduced Overall Symptomatic Hypoglycemia vs IGlar U100

13. SWITCH 2: Nocturnal Symptomatic Hypoglycemia - IDeg Significantly Reduced Nocturnal Symptomatic Hypoglycemia vs IGlar U100

14. DEVOTE: Trial Design

15. DEVOTE: Time to First MACE

16. Incidence of Hypoglycemia

17. Systematic Review: Association of Hypoglycemia With Outcomes

18. Advantages of New Insulin Analogues

19. Once-a-Day Injections: Advantages

20. ADA Practice Guidelines

21. PCP Point of View

22. ADA Practice Guidelines

23. PCP Point of View

24. Combination of Basal Insulin and GLP-1 RA: Advantages

25. Approved Combinations of Basal Insulin and GLP-1 RA

26. Fixed-Ratio Combinations: Advantages

27. Fixed-Ratio Combinations: How to Use?

28. DUAL VII Trial Design

29. Similar Mean HbA1c Levels Sustained Throughout the DUAL VII Trial

30. Effect on Hypoglycemia and Weight in DUAL VII

31. Effect on Doses of Insulin in DUAL VII Trial

32. Achievement of an HbA1c < 7% in DUAL VII Trial

33. Insulin Therapy in Clinical Practice

34. Clinical Inertia in Insulin Initiation and Titration

35. Insulin in ADA Guidelines

36. Conclusion

37. Abbreviations

38. Abbreviations (cont)